Baird lowered the firm’s price target on Sage Therapeutics (SAGE) to $7 from $9 and keeps a Neutral rating on the shares. The firm The firm adjusted its model following Q4 results and sees a long road to profitability.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities
- Sage Therapeutics price target lowered to $8 from $9 at Canaccord
- SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration
- Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties
- Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright